Neurodon

Neurodon is the only company harnessing and restoring Ca2+ with first-in-class modulators. Neurodon’s compounds have undergone extensive proof-of-concept studies in animal models of diabetes, obesity, neurodegenerative disorders, and rare diseases. There are no competitors in market targeting diseases with Neurodon’s MOA and industry-leading ER stress platform technology. We have 2 candidates in IND-enabling studies and plan to enter the clinic in 2025. Neurodon has raised >$11MM to date through a combination of state and federal grants (e.g. NIH), foundations (e.g. JDRF), partnerships, angel investments, and founder’s funds. Neurodon is currently raising a funding round to fund first in human studies for its diabetes and rare disease programs in 2025.

Neurodon headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical sector. The company focuses on Biotechnology and has secured $1.7B in funding across 176 round(s). With a team of 1-10 employees, Neurodon is actively contributing to advancements in Biotechnology. Their latest funding round, Equity Crowdfunding - Neurodon, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.